Update on Repros’ Androxal – Analyst Blog

By | September 14, 2012
0 Comment

Repros Therapeutics Inc. ( RPRX ) recently provided an update on its phase III program, Androxal indicated for the treatment of secondary hypogonadism. The company has started randomizing

Visit site:
Update on Repros’ Androxal – Analyst Blog

Related posts:

  1. McMoRan Issues GOM Ops Update – Analyst Blog
  2. Dean Foods Provides Update on IPO – Analyst Blog
  3. Secondary Offering by MAKO – Analyst Blog
  4. Phase III Data on Novartis’ RLX030 – Analyst Blog